Market report: Biotechs up for third week in a row
Saturday, 27 November, 2010
The S&P/ASX 200 Heathcare Index closed in the black on Friday for the third week in a row, as the wider market slipped for the second week in a row.
It closed the week up two percent to 8665.9 points, while the benchmark S&P/ASX 200 Index fell 31.2 points to 4598.
Biotech performer of the week was Cochlear which managed a gain of eight percent to close the week on $78.75. Things weren’t so bright for the other majors, with ResMed down 47 cents to $32.18, while market leader CSL added just 27 cents to close at $35.00.
Like the broader market, volumes were also thin for biotechs on Friday.
Looking at the best and worst performers, biologics company Circadian technologies fell 8.15 percent to $0.62 while antibody specialists Patrys closed the day down 4.76 percent to $0.10.
Among the stocks heading north, biomarker and diagnostics company Healthlinx gained 6.33 percent to $0.084, while spray-on-skin specialists Avita Medical gained 4.76 percent to close Friday on $0.10.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
